Reshaping the Approach to Therapeutic Development with i-Bodies

We met with Tim Oldham, Ph.D., CEO and Managing Director of AdAlta, on the campus of La Trobe University in Melbourne. Tim shares insights into AdAlta’s groundbreaking i-body platform, a next-generation human protein with superior abilities compared to traditional monoclonal antibodies. The i-body’s unique structure allows it to access grooves and cavities that other antibodies cannot reach, opening up new possibilities for treating debilitating diseases. Tim discusses how AdAlta is advancing therapeutic innovation and shaping the future of biotech.